- Home
- DSP vs SION Comparison
DSP vs SION Comparison
Compare DSP & SION Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSP
- SION
- Stock Information
- Founded
- DSP 1999
- SION 2019
- Country
- DSP United States
- SION United States
- Employees
- DSP N/A
- SION N/A
- Industry
- DSP EDP Services
- SION
- Sector
- DSP Technology
- SION
- Exchange
- DSP Nasdaq
- SION NYSE
- Market Cap
- DSP 291.3M
- SION 338.0M
- IPO Year
- DSP 2021
- SION 2025
- Fundamental
- Price
- DSP $14.12
- SION $12.32
- Analyst Decision
- DSP Strong Buy
- SION Strong Buy
- Analyst Count
- DSP 8
- SION 1
- Target Price
- DSP $21.75
- SION $32.00
- AVG Volume (30 Days)
- DSP 263.8K
- SION 130.5K
- Earning Date
- DSP 05-06-2025
- SION 05-25-2025
- Dividend Yield
- DSP N/A
- SION N/A
- EPS Growth
- DSP N/A
- SION N/A
- EPS
- DSP 0.13
- SION N/A
- Revenue
- DSP $306,484,000.00
- SION N/A
- Revenue This Year
- DSP $19.25
- SION N/A
- Revenue Next Year
- DSP $16.72
- SION N/A
- P/E Ratio
- DSP $109.37
- SION N/A
- Revenue Growth
- DSP 30.64
- SION N/A
- 52 Week Low
- DSP $8.62
- SION $7.26
- 52 Week High
- DSP $26.33
- SION $25.19
- Technical
- Relative Strength Index (RSI)
- DSP 55.48
- SION N/A
- Support Level
- DSP $12.58
- SION N/A
- Resistance Level
- DSP $15.31
- SION N/A
- Average True Range (ATR)
- DSP 0.80
- SION 0.00
- MACD
- DSP 0.15
- SION 0.00
- Stochastic Oscillator
- DSP 81.76
- SION 0.00
About DSP Viant Technology Inc.
Viant Technology Inc is an advertising software company. The software enables the programmatic purchase of advertising, which is the electronification of the advertising buying process. Through the technology, a marketer can easily buy ads on desktop, mobile, connected TV, linear TV, streaming audio and digital billboards.
About SION SIONNA THERAPEUTICS INC
Sionna Therapeutics Inc is a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein to deliver clinically meaningful benefit to CF patients. CF is a progressive and life-threatening genetic disease caused by inherited mutations in the CFTR gene, which heads to insufficient CFTR function. The Company is managed as one operating segment focused on the research and development of cystic fibrosis therapies.